Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.58 |
| ▸ | PPARG | P37231 | 5/20 | 0.55 |
| ▸ | CTSS | P25774 | 7/20 | 0.50 |
| ▸ | CTSK | P43235 | 7/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954493 | 1.00 | PPARA (0.58) | PPARAPPARGCTSSCTSKCYP1A2 | |
| SCHEMBL4845923 | 1.00 | PPARA (0.58) | PPARAPPARGCTSSCTSKCYP1A2 | |
| SCHEMBL21837472 | 0.87 | PPARA (0.55) | PPARAPPARGCTSSCTSKCYP1A2 | |
| SCHEMBL21837471 | 0.87 | PPARA (0.55) | PPARAPPARGCTSSCTSKCYP1A2 | |
| SCHEMBL24633954 | 0.87 | PPARA (0.55) | PPARAPPARGCTSSCTSKCYP1A2 | |
| SCHEMBL16170321 | 0.87 | CYP1A2 (0.47) | PPARAPPARGCTSSCTSKCYP1A2 | |
| SCHEMBL14842431 | 0.85 | CYP1A2 (0.49) | PPARAPPARGCTSSCTSKCYP1A2 | |
| SCHEMBL14842430 | 0.85 | CYP1A2 (0.49) | PPARAPPARGCTSSCTSKCYP1A2 | |
| SCHEMBL25892128 | 0.85 | PPARA (0.56) | PPARAPPARGCTSSCTSKCTSL | |
| SCHEMBL13897471 | 0.85 | PPARA (0.56) | PPARAPPARGCTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024163962-A1 | 3-((1,1-DIOXIDO-2,3,4,5-TETRAHYDROBENZO[F][1,2,5]THIADIAZEPIN-8-YL)OXY)-2-FLUOROACRYLIC ACID DERIVATIVES AS SODIUM TAUROCHOLATE CO-TRANSPORTING POLYPEPTIDE (NTCP) INHIBITORS FOR THE TREATMENT OF CHOLESTASIS | Hemoshear Therapeutics, Inc. (US) | 2024-08-08 | — | — | WO | disclosed |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| EP-4326724-A1 | COMPOUND AS ADENOSINE A2A RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2024-02-28 | — | — | EP | disclosed |
| CN-117120443-A | Compounds as adenosine A2a receptor antagonists and pharmaceutical compositions containing the same | 株式会社 钟根堂 | 2023-11-24 | — | — | CN | disclosed |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2022224180-A1 | COMPOUND AS ADENOSINE A2A RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2022-10-27 | — | — | WO | disclosed |
| US-20220306634-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA SAN DIEGO, INC. | 2022-09-29 | — | — | US | disclosed |
| EP-3825316-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2021-05-26 | — | — | EP | disclosed |
| EP-3489236-B1 | PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-30 | — | — | EP | disclosed |
| CN-102753548-A | Fused heteroaromatic pyrrolidones as SYK inhibitors | TAKAEDA CHEMICAL IND LTD | 2012-10-24 | — | — | CN | disclosed |
| WO-2011079051-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-23 | — | — | US | disclosed |
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| EP-1567489-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1695961-A1 | UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | GLAXO GROUP LIMITED (GB) | 2006-07-27 | — | — | US | disclosed |
| EP-1546134-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | ELI LILLY AND COMPANY (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004014895-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | ELI LILLY AND COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306634-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | PPARA 2060/4885PPARG 1437/4885CTSS 1771/4885 |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | PPARA 2060/4885PPARG 1437/4885CTSS 1771/4885 |
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | TFPI, TFPI2, SERPINC1 | PPARA 3210/4885PPARG 3822/4885CTSS 380/4885 |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | PPARA 4634/4885PPARG 4344/4885CTSS 2756/4885 |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ADORA2A, ADORA1, ADORA2B | PPARA 661/4885PPARG 659/4885CTSS 3301/4885 |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | PPARA 2060/4885PPARG 1437/4885CTSS 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.